ASCO 2022: Panitumumab Plus mFOLFOX6 for Certain Patients With Metastatic Colorectal Cancer
Posted: 06/07/2022 | By: Chase Doyle

Question 1 of 5

In the full-analysis set, with a median follow-up of 61 months, patients with RAS wild-type metastatic colorectal cancer randomly assigned to receive panitumumab plus mFOLFOX6 as first-line treatment survived for a median of how many months?

Choose 1